3.27
-0.27 (-7.63%)
| Previous Close | 3.54 |
| Open | 3.48 |
| Volume | 3,962,227 |
| Avg. Volume (3M) | 4,416,120 |
| Market Cap | 1,157,006,208 |
| Price / Earnings (Forward) | 9.14 |
| Price / Sales | 167.04 |
| Price / Book | 29.92 |
| 52 Weeks Range | |
| Earnings Date | 25 Mar 2026 |
| Operating Margin (TTM) | -1,685.01% |
| Diluted EPS (TTM) | -0.550 |
| Quarterly Revenue Growth (YOY) | 25.90% |
| Total Debt/Equity (MRQ) | 35.04% |
| Current Ratio (MRQ) | 3.53 |
| Operating Cash Flow (TTM) | -70.41 M |
| Levered Free Cash Flow (TTM) | -53.20 M |
| Return on Assets (TTM) | -44.04% |
| Return on Equity (TTM) | -278.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Precigen, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | 3.0 |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.00 |
|
Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.56% |
| % Held by Institutions | 67.08% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Patient Capital Management, Llc | 31 Dec 2025 | 18,673,466 |
| Tang Capital Management Llc | 31 Dec 2025 | 5,617,500 |
| Diametric Capital, Lp | 31 Dec 2025 | 3,847,024 |
| Iridian Asset Management Llc/Ct | 31 Dec 2025 | 3,600,195 |
| Occam Crest Management Lp | 31 Dec 2025 | 3,501,739 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AGEE NANCY H | 3.51 | - | 16,096 | 56,497 |
| ALVAREZ CESAR L | 3.51 | - | 17,806 | 62,499 |
| FRANK STEVEN | 3.51 | - | 14,245 | 50,000 |
| GUPTA VINITA D | 3.51 | - | 17,948 | 62,997 |
| HASSAN FRED | 3.51 | - | 17,948 | 62,997 |
| KINDLER JEFFREY B | 3.51 | - | 19,658 | 69,000 |
| KIRK RANDAL J | 3.51 | - | 28,490 | 100,000 |
| TURLEY JAMES S | 3.51 | - | 17,806 | 62,499 |
| Aggregate Net Quantity | 149,997 | |||
| Aggregate Net Value ($) | 526,489 | |||
| Aggregate Avg. Buy ($) | 3.51 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AGEE NANCY H | Director | 10 Mar 2026 | Acquired (+) | 16,096 | 3.51 | 56,497 |
| ALVAREZ CESAR L | Director | 10 Mar 2026 | Acquired (+) | 17,806 | 3.51 | 62,499 |
| FRANK STEVEN | Director | 10 Mar 2026 | Acquired (+) | 14,245 | 3.51 | 50,000 |
| GUPTA VINITA D | Director | 10 Mar 2026 | Acquired (+) | 17,948 | 3.51 | 62,997 |
| HASSAN FRED | Director | 10 Mar 2026 | Acquired (+) | 17,948 | 3.51 | 62,997 |
| KINDLER JEFFREY B | Director | 10 Mar 2026 | Acquired (+) | 19,658 | 3.51 | 69,000 |
| TURLEY JAMES S | Director | 10 Mar 2026 | Acquired (+) | 17,806 | 3.51 | 62,499 |
| KIRK RANDAL J | Director | 10 Mar 2026 | Acquired (+) | 28,490 | 3.51 | 100,000 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |